Regenxbio: Fairly Valued Given The Current Risks But Could Have Eye-Watering Upside

by: Value Kicker
This article is exclusive for subscribers.
Value Kicker
Long only, value, growth at reasonable price, CFA

Regenxbio's main product, RGX-314, for wet AMD has a large potential market but with many competitors.

RGX-314 is competitive with current treatments with a mix of pros and cons.

Even though I am not entirely sold on the blockbuster potential of RGX-314, valuation wise, it is fairly valued. There is a potential upside with the pipeline and NAV technology platform.

Regenxbio (RGNX) is a clinical-stage biotechnology focusing on gene therapy. Gene therapy products are designed to deliver genes to cells to address genetic defects or to enable cells in the body to produce